Journal ArticleOPEN ACCESS

Thalidomide for the treatment of angiodysplasia-related recurrent gastrointestinal hemorrhage: Is low dose a safe and viable option?

Clinical Case Reports (2019) 7(12) 2363-2367
DOI: 10.1002/ccr3.2501
2Citations
Citations of this article
7Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Thalidomide is often used for the management of refractory gastrointestinal angiodysplasia (GIAD). The tolerance, toxic profile, and compliance of thalidomide are dose-dependent. The low-dose thalidomide (50 mg) is safe and a viable option for bleeding related to GIAD.

Author supplied keywords

Cite

CITATION STYLE

APA

Patel, H., Mehershahi, S., Shaikh, D. H., Makker, J., Nayudu, S., Remy, P., & Chilimuri, S. (2019). Thalidomide for the treatment of angiodysplasia-related recurrent gastrointestinal hemorrhage: Is low dose a safe and viable option? Clinical Case Reports, 7(12), 2363–2367. https://doi.org/10.1002/ccr3.2501

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free